Lead Product(s) : NMT.001
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Angelini Ventures
Deal Size : $20.9 million
Deal Type : Series A Financing
Angelini, Neumirna Lead €20M Series A for RNA Therapy in Neurological Disorders
Details : The proceeds from the financing will enable Neumirna to advance its lead asset NMT.001 for the treatment of epilepsy.
Product Name : NMT.001
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : NMT.001
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Angelini Ventures
Deal Size : $20.9 million
Deal Type : Series A Financing
Lead Product(s) : IRX4204
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Io Therapeutics Presents IRX4204 Results for ALS Treatment
Details : IRX4204 is the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS).
Product Name : IRX4204
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2024
Lead Product(s) : IRX4204
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TPT0201
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Tetra Pharm Technologies
Deal Size : Undisclosed
Deal Type : Collaboration
Tetra Pharm and Glysious Partner to Develop Transdermal Endocannabinoid System Drugs
Details : The collaboration aims to revolutionize transdermal release of difficult-to-formulate compounds, including TPT0201, studied for mild cognitive impairment, targeting the endocannabinoid system.
Product Name : TPT0201
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 24, 2024
Lead Product(s) : TPT0201
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Tetra Pharm Technologies
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VES001
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Michael J. Fox Foundation for Parkinson’s Research
Deal Size : $0.8 million
Deal Type : Funding
Vesper Bio Awarded Grant to Assess Sortilin Inhibitors for Parkinson's
Details : The funding aims to support the clinical advancement of Vesper's lead product VES001, a sortilin inhibitor. Currently, it is being evaluated in the preclinical trial studies for Parkinson's disease.
Product Name : VES001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : VES001
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Michael J. Fox Foundation for Parkinson’s Research
Deal Size : $0.8 million
Deal Type : Funding
Lead Product(s) : Recombinant Human Meteorin
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Indaco Venture Partners
Deal Size : $25.0 million
Deal Type : Series A Financing
Details : The net proceeds will be used to advance new drug candidate, HB-086, a non-opioid compound with a unique mode of action, targeting the underlying cause in the peripheral nervous system against chronic neuropathic pain.
Product Name : HB-086
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 12, 2023
Lead Product(s) : Recombinant Human Meteorin
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Indaco Venture Partners
Deal Size : $25.0 million
Deal Type : Series A Financing
Lead Product(s) : Semaglutide
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo Nordisk To Enter Phase 3 Development in Alzheimer’s Disease with Oral Semaglutide
Details : Novo Nordisk announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide.
Product Name : Rybelsus
Product Type : Peptide
Upfront Cash : Inapplicable
December 16, 2020
Lead Product(s) : Semaglutide
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Michael J. Fox Foundation for Parkinson’s Research
Deal Size : Undisclosed
Deal Type : Collaboration
Orphazyme to Collaborate with The Michael J. Fox Foundation on Parkinson’s Disease Research
Details : Orphazyme’s drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson’s disease (PD).
Product Name : Miplyffa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 17, 2020
Lead Product(s) : Arimoclomol Citrate
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Michael J. Fox Foundation for Parkinson’s Research
Deal Size : Undisclosed
Deal Type : Collaboration